XIAP is being targeted as a cancer therapeutic because its inhibition of caspases promotes resistance to cancer therapeutics that induce apoptosis including tumour-necrosis factor (TNF)-related apoptosis-inducing lingand (TRAIL) and various chemotherapeutics [23, 27, 28]. The gene discussed is XIAP; the disease is cancer.